NeoStem has signed a definitive agreement to acquire California Stem Cell, Inc., and plans to begin a Targeted Immunotherapy Program that targets cancer initiating cells, starting with a Phase 3 trial for melanoma.
Learn More - reading our press release
Enhancingthe body’s healing response.
Rebalancingthe immune system.
Unlockingthe power of VSELs.
NeoStem Profile by BTV
Business Television, an investment news program profiling emerging and publicly traded companies, visited NeoStem to speak with Chairman and CEO, Dr. Robin Smith and Chief Medical Officer, Dr. Douglas Losordo, about the company.
News + Events
NeoStem Announces Definitive Agreement to Acquire California Stem Cell, Inc. April 14, 2014 - Learn More
NeoStem Welcomes Dr. Adel Nada as Vice President, Immunotherapy April 3, 2014 - Learn More
NeoStem and Progenitor Cell Therapy (PCT) to Present at Multiple April Conferences April 1, 2014 - Learn More
To briefly introduce myself, I am an interventional cardiologist by training and serve as the Chief Medical.... Read More